Onkologie. 2009:3(2):99-100

Molecular biology of renal cancer

Magdalena Čížková
Laboratoř experimentální medicíny, UP Olomouc

Renal cancer comprises a set of distinct subtypes arising from cell populations of the renal parenchyma. Each of these cancer subtypes

bears characteristic genetic changes that are observed in both familial and sporadic cases. This article provides an overview of the genetic

alterations described in the literature. It also deals with the prognostic and predictive markers and the options for minimally invasive

screening methods using blood and urine samples.

Keywords: renal cancer, genetic alterations, prognosis, prediction.

Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čížková M. Molecular biology of renal cancer. Onkologie. 2009;3(2):99-100.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Antonelli A, Portesi E, Cozzoli A, et al. The collecting duct carcinoma of the kidney: a cytogenetical study. Eur Urol. 2003; 43(6): 680-685. Go to original source... Go to PubMed...
    2. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005; 11(10): 3714-3721. Go to original source... Go to PubMed...
    3. Brunelli M, Gobbo S, Cossu-Rocca P, et al. Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma. Mod Pathol. 2007; 20(3): 303-309. Go to original source... Go to PubMed...
    4. Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004; 28(4): 435-441. Go to original source... Go to PubMed...
    5. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008; 113(3): 450-460. Go to original source... Go to PubMed...
    6. Delahunt B. Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies. Pathology. 1999; 31(3): 185-190. Go to original source... Go to PubMed...
    7. Dudderidge TJ, Stoeber K, Loddo M, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 2005; 11(7): 2510-2517. Go to original source... Go to PubMed...
    8. Fischer J, Palmedo G, von Knobloch R, et al. Duplication and overexpression of the mutant allele of the MET protooncogene in multiple hereditary papillary renal cell tumours. Oncogene. 1998; 17(6): 733-739. Go to original source... Go to PubMed...
    9. Gilbert SM, Whitson JM, Mansukhani M, et al. Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology. 2006; 67(5): 942-945. Go to original source... Go to PubMed...
    10. Gunawan B, von Heydebreck A, Fritsch T, et al. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res. 2003; 63(19): 6200-6205. Go to original source...
    11. Hora M. Nádory ledviny. Urologie pro praxi 2005; 1: 28-30.
    12. Hughson MD, Dickman K, Bigler SA, Meloni AM, Sandberg AA. Clear-cell and papillary carcinoma of the kidney: an analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification, cytogenetics, and fluorescence in situ hybridization. Cancer Genet Cytogenet. 1998; 106(2): 93-104. Go to original source... Go to PubMed...
    13. Jiang F, Richter J, Schraml P, et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol. 1998; 153(5): 1467-1473. Go to original source... Go to PubMed...
    14. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007; 13(2 Pt 2): 680s-684s. Go to original source... Go to PubMed...
    15. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001; 7(10): 3113-3119.
    16. Kardas I, Mrózek K, Babinska M, et al. Cytogenetic and molecular findings in 75 clear cell renal cell carcinomas. Oncol Rep. 2005; 13(5): 949-956. Go to original source... Go to PubMed...
    17. Klatte T, Böhm M, Nelius T, Filleur S, Reiher F, Allhoff EP. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma. BJU Int. 2007; 100(1): 209-214. Go to original source... Go to PubMed...
    18. Lim DL, Ko R, Pautler SE. Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists. Can Urol Assoc J. 2007; 1(2 Suppl): S13-S20. Go to original source... Go to PubMed...
    19. Linehan WM, Vasselli J, Srinivasan R. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004; 10: 6282S-6289S. Go to original source... Go to PubMed...
    20. Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 2002; 1(5): 459-468. Go to original source... Go to PubMed...
    21. Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 1999; 154(4): 981-986. Go to original source... Go to PubMed...
    22. Ozer G, Altinel M, Kocak B, Yazicioglu A, Gonenc F. Value of urinary NMP-22 in patients with renal cell carcinoma. Urology. 2002; 60(4): 593-597. Go to original source... Go to PubMed...
    23. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007; 109(11): 2257-2267. Go to original source... Go to PubMed...
    24. Ramankulov A, Lein M, Johannsen M, et al. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett. 2008; 269(1): 85-92. Go to original source... Go to PubMed...
    25. Schraml P, Struckmann K, Hatz F, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol. 2002; 196(2): 186-193. Go to original source... Go to PubMed...
    26. Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol. 1997; 183(2): 151-155. Go to original source... Go to PubMed...
    27. Schwerdtle RF, Störkel S, Neuhaus C, et al. Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma. Cancer Res. 1996; 56(13): 2927-2930.
    28. Steiner G, Cairns P, Polascik TJ, et al. High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1-32.2. Cancer Res. 1996; 56(21): 5044-5046.
    29. Takahashi M, Oka N, Naroda T, et al. Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. Int J Urol. 2002; 9(10): 531-538. Go to original source... Go to PubMed...
    30. Teratani T, Domoto T, Kuriki K, et al. Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma. Urology. 2007; 69(2): 236-240. Go to original source... Go to PubMed...
    31. Waldert M, Haitel A, Marberger M, et al. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int. 2008; 102(10): 1381-1384. Go to original source... Go to PubMed...
    32. Zigeuner R, Droschl N, Tauber V, Rehak P, Langner C. Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique. Urology. 2006; 68(3): 518-522. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.